Objectives: Analyze the oncologic and functional outcomes in patients affected by low risk prostate cancer underwent prostate cryotherapy. Materiasl and methods: It's a prospective tricentric study of 434 patients treated with prostate cryoablation for low risk prostate cancer. By low risk we refer to the D'Amico's risk classification. Two cycles of freezing/thawing are run for each patient following the technique described by Onik. Results: For the 434 patients, the median age was 66 years with a standard deviation of ± 6.68, the average PSA was 6.17 ng/d/L, the median 5.55 with a standard deviation of ± 2.13, the mean prostate volume was 35.59 cc, the median 34.00 cc, with a standard deviation of ± 7.89. Biochemical failure occurred in 67 patients (15.4%). Pre-operative erectile function in men was distributed as follows: severe in 95 patients (19.2%), moderate in 95 (19.2%), medium-moderate in 180 (36.4%), mild in 92 (18.6%), with no dysfunction in 32 (6.5%) patients. Post-operative erectile function, measured 1 month after cryotherapy, was distributed as follows: severe in 321 (65%) patients, moderate in 69 (14%), medium-moderate in 79 (16%), mild in 23 (4.7%), and no dysfunction in only 2 patients (0.4%). Post-operative erectile function after 3 months was distributed as follows: severe in 233 (47.2%) patients, moderate in 66 (13.4%), medium-moderate in 122 (24.7%), mild in 65 (13.2%), and no dysfunction in 8 patients (1.6%). Urinary incontinence was present in 21 patients (4.8%) after 3 months while it dropped to 13 patients (2.9%) after 6 months. Conclusions: Cryotherapy in the treatment of prostate cancer remains a viable alternative. The availability of new cryoprobes and the use of new diagnostic means such as fusion magnetic resonance will make this more precise and more effective method.
KEY WORDS: Prostate cryotherapy; Minimally invasive treatment; Focal therapy; Low risk prostate cancer. Currently there are many different options for treatments of prostate cancer, particularly for the low risk variety from D'Amico's risk classification (2) . According to the latest EAU guidelines there are different types of standard treatments for low risk prostate cancer. In recent years, with the aim of reducing the risk of overtreatment in this subgroup of patients, two conservative management strategies have been proposed: watchful waiting and active surveillance (3) . Surgical treatment of PCa consists of the radical prostatectomy (RP). In low risk patients the gold standard of care is the nerve sparing technique. The goal of surgery is to eradicate the disease by preserving continence and sexual potency when possible (4) . Pelvic lymph node dissection (LND) is not required for low-risk tumors because the risk of positive lymph nodes does not exceed 5%, according to Briganti's nomograms (5) . Radiotherapy for prostate cancer is an important and safe alternative to surgery and is the only form of curative treatment (6) (7) . For the treatment of clinically localized prostate cancer new therapeutic approaches have emerged as alternative therapeutic options: defined focal therapies that include two methods, the HIFU (high-intensity focused ultrasound) and Cryotherapy (CSAP) (8) (9) . The use of cryosurgery has been enhanced thanks to the introduction of a modern percutaneous approach using trans-rectal ultrasound probe introduced by Onik et al. in 1993 (8) . In 2008 the AUA's best practice statement on cryosurgery affirmed that cryosurgery is an option for patients with an organ confined disease (10) . The aim of this study is to investigate the oncological and functional outcomes in patients affected by low-risk prostate cancer.
MATERIALS AND METHODS
Our is a prospective tricentric study of 434 patients treated with prostate cryoablation for low risk prostate cancer. By low risk we refer to the D'Amico risk classifi-
INTRODUCTION
In the era of the PSA screening the detected rate of prostate cancer has dramatically increased (1).
cation of clinical stage (< T2a, PSA levels < 10.0 ng/mL, and a Gleason score ≤ 6). All patients were operated on using the same surgical technique, performed by the same surgeon in 80% of cases. The surgery was performed under general anesthesia. Patient preparation includes cleansing with enema and broad spectrum antibiotic prophylaxis. The patient is in the dorsal lithotomy position, in this way facilitating the exposure of the perineum and the movements of the rectal probe (Probe longitudinal biplane to 7.5 Hz). In all cases the coaxial system Stryker Cryo/44 was used with cryoprobes of 2.4 mm in diameter, from six to eight in number depending on prostate volume. Cryoablation involves 2 cycles, one freezing and one cooling; respectively exploiting cycles of pressurized gas, argon (300 bar of pressure and -180°C) for the freezing cycle and helium for the heating cycle (200 bar of pressure with -180°C temperature exchange to 40°C in 30 seconds). The temperature is monitored inside and outside of the prostate. Thermal sensors, are positioned in the apex, external sphincter, and neurovascolar bundle to the right and to the left of the gland. Hydrodistention of the rectal area prostate was performed by injecting saline solution mixed with broad-spectrum antibiotic in the Denonvilliers' fascia (Onik maneuver band). Control cystoscopy is performed in order to ensure integrity of the urethra, which is protected by means of an FDA-approved continuous flow system with a pump pressure of 4.5 bar, which puts blue methylene physiological solution into circulation at 41°C and keeps adjacent tissues at a temperature of 38°C (11) (12) (13) (14) . At each cryoablation two complete cycles of freezing/ thawing are run. Depending on prostate volume or on prostates with a larger longitudinal diameter of 35 mm, a third cycle with a distal displacement of 10 millimeters of cryoprobes was necessary, in a maneuver referred to as "pull back". The patients were discharged within 24 hours, with a catheter in place for two weeks and were given antiinflammatory drugs for the pain (8) . Biochemical recurrence was determined according to the Phoenix defined by ASTRO criteria as a rising PSA, above the Nadir of more than 2 ng/mL (15) . Follow-up was carried out in hospital laboratories by monitoring PSA level every month for the first three months and then once every six months for a total of 54 months.
Statistical analysis
Statistical analysis was performed with Stata 14 software by StataCorp, descriptive variables were analyzed using mean, median, standard deviation, and a 95% confidence interval (95% CI). The survival curves were described using the Kaplan-Meier method. After making the appropriate test for normality (Shapiro-Wilk test) to validate if the assumptions underlying the model were statistically satisfied. We applied the model of analysis of variance in our sample.
RESULTS
For the 434 patients, the median age was 66 years with a standard deviation of ± 6.68, the average PSA was 6.17 ng/dL, the median 5.55 with a standard deviation of ± 2.13, the mean prostate volume was 35.59 cc, the median 34.00 cc, with a standard deviation of ± 7.89. Biopsies performed on patients for pre-intervention of disease diagnosis were conducted trans-rectally in 421 patients (97%), and trans-perineally in 13 patients (3%). Biochemical failure occurred in 67 patients (15.4%) (Figures 1-2) . The survival curve it's shown in the Kaplan-Meier graph ( Figure 3) . The average hospital stay was for 1.89 days, with a median of 1 and a standard deviation of ± 1.48.
Pre-operative erectile function in men (Figure 4 ) was distributed as follows: severe in 95 patients (19.2%), moderate in 95 (19.2%), medium-moderate in 180 (36.4%), mild in 92 (18.6%), with no dysfunction in 32 (6.5%) patients. Post-operative erectile function, measured 1 month after cryotherapy (Figure 4) , was distributed as follows: severe in 321 (65%) patients, moderate in 69 (14%), mediummoderate in 79 (16%), mild in 23 (4.7%), and no dysfunction in only 2 patients (0.4%). Post-operative erectile function (Figure 4 ) after 3 months was distributed as follows: severe in 233 (47.2%) patients, moderate in 66 (13.4%), medium-moderate in 122 (24.7%), mild in 65 (13.2%), and no dysfunction in 8 patients (1.6%). In 87% of cases (377 patients) two freeze and thaw cycles were applied while three cycles were applied in the remaining 13% of patients (57 patients) due to the size and/or morphology of the prostate. Number 4 needles were used in 68 patients (15.6%), number 6 needles in 290 patients (67.4%), and number 8 needles were used in 73 patients (17%). Urinary incontinence was present in 21 patients (4.8%) after 3 months while it dropped to 13 patients (2.9%) after 6 months. 
DISCUSSION
Cryotherapy for the treatment of prostate cancer is a technique that was originally introduced in 1960, but was soon abandoned because of excessive morbidity (11) (12) (13) . The use of this therapeutic approach has increased with its reintroduction by Onik et al. in 1993 thanks to the introduction of a modern percutaneous approach with the aid of a trans-rectal ultrasound probe (8) . The treatment itself has undergone an evolution over decades of application in clinical practice; the development of interventional radiology has improved cryogenic technology and provided a better understanding of cryobiology (16) (17) . The action mechanism of cryotherapy is complex. It exerts its effect by: the induction of protein denaturation, dehydration, rupture of the cell membrane due to expansion of ice crystals, the transfer of water from the intracellular side to extracellular spaces, vascular stasis, the induction of apoptosis, increasing the concentration of toxic substances at the intracellular level and finally osmotic shock (8, (11) (12) (13) (14) . Traditionally, supporters of cryotherapy as primary treatment for prostate cancer have sustained that the procedure offers advantages over conventional treatments, allowing a non-invasive treatment of cancer in patients who are very elderly or are suffering from multi-comorbidity and would otherwise not be eligible candidates for traditional surgery; in recent years refinement of the procedure has also allowed an increase in effectiveness and safety. Our data on survival free from biochemical recurrence after a follow-up of 54 months proves that this procedure produces efficacy rates that are highly competitive with all other conventional forms of therapy recommended by European and international guidelines; above all with three-dimensional radiation therapy, conformational radiotherapy or brachytherapy. As a result, there is no definitive oncological comparative data. However, in a recent comparative study between cryoablation and radiation therapy conducted on 244 patients no significant differences between the two groups (76%) were found (15) . In another trial a PSA nadir of less than 0.4 ng/ml in 81% of patients was shown without biochemical progression for 12 months of study.
In another single-center study with 590 patients and a mean follow-up of 7 years, the percentage of patients free of biochemical recurrence was approximately 61% (16). However, not all data in the literature support the idea that cryotherapy and radiotherapy are equivalent, especially in high-risk patients. UAE guidelines, compared with AUA guidelines, show a substantial difference in classifying candidate patients for cryotherapy; in fact, in Europe, the "model" patient remains the low risk patient, whereas in the United States the procedure has been extended to cases of higher risk, as long as the disease is organ-confined. Another aspect to consider is the comparison with invasive treatments such as radical prostatectomy. Gould et al.
have shown a lower incidence of biochemical recurrence in patients who underwent cryotherapy compared to radical prostatectomy. This study presents several biases and was conducted on a small number of patients (18) . Active surveillance is one of the treatment options for patients at low risk of prostate cancer. Klotz et al. have analyzed patients ranging from T1c and T2a, PSA < 10 ng/mL, Gleason score < 6, or PSA < 15 ng/mL for patients older than 70 years with Gleason < 7 (3 + 4) (19) (20) .
With an average follow-up of 6.8 years, survival at 10 years was 97.2%. For the 62% of patients who were still in active surveillance, 30% underwent radical prostatectomy; 10% preferred to switch to active treatment due to a PSA doubling time < 3 years or an advancing Gleason score. The collective survival varies from 70% to 100%. Biochemical failure has occurred in 13% of patients undergoing active surveillance (21 In terms of quality of life, there are several studies that compare cryotherapy as a treatment for a locally advanced tumor. Patients treated with cryotherapy and brachytherapy reported a higher score of urinary disorders when compared with radical prostatectomy (27) .
Since it was adopted, robotic prostatectomy has not shown significant benefits in functional outcome compared with the open approach. Ball et al. compared 719 patients treated with open, laparoscopic and a robotic approach, as well as brachytherapy and cryotherapy (28) . Men treated with brachytherapy and cryotherapy were older and had more co-morbidities. The analysis demonstrated that cryotherapy has a negative impact on erectile function with respect to brachytherapy, and that this effect is reduced to 3 and 6 months, while the irritative and obstructive symptoms were higher in brachytherapy. In patients undergoing cryotherapy, worse sexual outcomes were demonstrated than in other treatments, but the baseline was also lower.
CONCLUSIONS
Cryotherapy in the treatment of PCa remains a viable alternative to more invasive approaches. The availability of new cryoprobes and the use of new diagnostic means such as fusion magnetic resonance will make this more precise and more effective method.
